First National Bank of Omaha Takes $3.97 Million Position in Elanco Animal Health Incorporated $ELAN

First National Bank of Omaha acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 160,631 shares of the company’s stock, valued at approximately $3,974,000.

Several other large investors have also recently modified their holdings of ELAN. Parallel Advisors LLC boosted its stake in Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after acquiring an additional 392 shares in the last quarter. Sapient Capital LLC increased its position in shares of Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after purchasing an additional 420 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after purchasing an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its holdings in shares of Elanco Animal Health by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after purchasing an additional 428 shares during the last quarter. Finally, Meeder Advisory Services Inc. boosted its position in shares of Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 0.1%

Shares of ELAN stock opened at $23.63 on Wednesday. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The firm has a market capitalization of $11.80 billion, a PE ratio of -57.63, a P/E/G ratio of 1.42 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock’s 50-day simple moving average is $24.54 and its 200-day simple moving average is $24.01.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the prior year, the firm earned $0.26 earnings per share. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $23.08 per share, with a total value of $96,936.00. Following the acquisition, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Shiv O’neill bought 3,998 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 23,198 shares of company stock valued at $537,109. Company insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. UBS Group raised their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley boosted their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.